# Diabetes Research Hub — Monitor Report
**Run date:** 2026-09-26 (scheduled review)
**Prior report on file:** 2026-09-25

---

## File System Status

No pipeline has run since the last review — nothing in `Analysis/` is newer than 2026-09-25 12:00 UTC, and the workspace's last commit (`8c2974f`, "Daily iteration 2026-09-25") is still the tip.

| File | Last modified | Age | Status |
|---|---|---|---|
| `clinical_trials_latest.json` | 2026-07-17 | **71 days** | **STALE** — unchanged; flagged in every review since at least 09-24 |
| `hub_monitor_report.md` | 2026-07-17 | **71 days** | **STALE** — unchanged; hub_monitor.py still has not run |
| `Diabetes_Research_Tracker.xlsx` | 2026-07-17 | **71 days** | **STALE** — unchanged |
| `pubmed_recent_latest.json` | 2026-09-23 | 3 days | Aging — no new PubMed pull since 09-23 |
| `literature_gap_data.json` | 2026-09-19 | 7 days | Aging — same underlying data reported for a week |
| `literature_gap_report.md` | 2026-09-25 | 1 day | Fresh render, same 09-19 data, same top-5 gaps as prior reports |
| `RESEARCH_DOCTRINE.md` | 2026-08-31 | 26 days | OK (doctrinal, low churn expected) |

**Unresolved, escalating — git push blocked (P0, flagged since at least 2026-09-15, 11+ days unactioned):**
The working tree is **123 commits ahead of `origin/main`**, which is still frozen at 2026-04-20. `git push` fails because the sandbox has no credential helper (`fatal: could not read Username for 'https://github.com'`). This means the fabricated "belatacept: 70% graft survival at 10 years" clinical figure — corrected in the repo on 2026-09-21 (commit `f6d0db4`) — **is still live on the public-facing site today**, 5 days after the fix was committed. Nothing produced by this hub since April is visible to any external reader. This requires a PAT provisioned for the scheduled task; it cannot be fixed from inside a review run.

A stale `.git/index.lock` is also present and this session could not remove it (`Operation not permitted`) — worth checking that no other process is mid-write.

---

## Clinical Trial Changes

`clinical_trials_latest.json` is still the 2026-07-17 pull (858 trials) — unchanged for 71 days despite daily snapshot files continuing to be generated through 2026-09-06 (894 trials) before that process also stopped. The "latest" pointer and the periodic-snapshot process appear to be two different broken things: snapshots ran through Sep 6 without ever promoting to `_latest.json`, and no snapshot at all has landed in 20 days.

Comparing the two most recent real snapshots (2026-09-01 → 2026-09-06, the newest available):
- **8 new trials**, including **Novo Nordisk's AMBITION 7 (NCT07797335)** — Phase 3, RECRUITING, testing zenagamtide for glycemic control — and **Eli Lilly's orforglipron obesity trial (NCT05872620)**, which completed.
- **3 status changes**, including Novo's insulin icodec Phase 3 trial (NCT07076199) moving RECRUITING → ACTIVE_NOT_RECRUITING, and Medtronic's MiniMed GATEWAY AID trial doing the same.
- No new results postings in that window.

Key Phase 3 trials still RECRUITING per the (stale) latest data: Vertex VX-880 (2 trials, T1D cell therapy), Eli Lilly's baricitinib trials (NCT07222332, NCT07222137, beta-cell preservation), Novo's CagriSema (NCT07564414) and icodec (NCT07076199 — now stale per above), and AstraZeneca's elecoglipron (NCT07662135). Sana Biotechnology has 0 matching trials in this dataset.

## PubMed Highlights

No new pull since 2026-09-23 (154 unique papers, 30-day lookback). Standing findings, unchanged for 3 days:
- **17 cross-domain papers**, the strongest being teplizumab work spanning T1D Immunotherapy (4 papers), and a T1D Stem Cell Cure × Immunotherapy paper on hypoimmune islet gene-editing (PMID 42626948).
- Key-therapy mentions: dapagliflozin (45), orforglipron (13), retatrutide (13), teplizumab (7), icodec (7), CagriSema (4), baricitinib (2), **zimislecel (0)** — still no PubMed coverage of Vertex's cell therapy by that name.
- Domain activity: T2D GLP-1 New (204), Diabetes AI/ML (198), and Diabetes Microbiome (137) are the most active; LADA New Research (11), Diabetes Epigenetics (4), Drug Repurposing (4), and GLP-1 Pharmacogenomics (2) remain the thinnest.

## Gap Analysis Summary

Same top-5 gaps as the last two reports (data still from 2026-09-19):
1. Beta Cell Regen × Health Equity (gap 100, 0 joint pubs)
2. Insulin Resistance × Islet Transplant (gap 100, 1 joint pub)
3. Islet Transplant × Drug Repurposing (gap 100, 0 joint pubs)
4. Islet Transplant × Health Equity (gap 100, 0 joint pubs)
5. Gene Therapy × LADA (gap 100, 0 joint pubs)

Three of the top 12 gaps involve **Drug Repurposing** (with Islet Transplant, Glucokinase, and Health Equity) — this is the strongest alignment with a Tier 1 doctrine area (`RESEARCH_DOCTRINE.md` #4, Drug Repurposing Computational Screening, score 18/20) and the most defensible place for new computational work if/when this gets picked up.

## Breaking News

Checked "diabetes breakthrough 2026" and "FDA diabetes approval 2026" (last 7 days) — no genuinely new items. Lilly's Onswik (insulin efsitora alfa-gobe) and Foundayo (orforglipron, obesity) approvals both pre-date this window and are already reflected in prior reports / the trial data above.

## Recommended Actions

Unchanged from yesterday and now compounding — nothing has been actioned:

1. **Provision a git credential (PAT) for the scheduled task.** This is the highest-priority open item: it is the only blocker keeping a known-fabricated clinical figure live on the public site 5 days after the fix was committed, and it is blocking 123 commits / 5+ months of work.
2. **Diagnose the clinical-trials pipeline** — `clinical_trials_latest.json` is 71 days stale and the promotion-to-latest step looks broken independent of the snapshot cadence, which itself stalled 20 days ago. Run `python baseline_clinical_trials.py` and check why 2026-09-06's snapshot never became `_latest.json`.
3. **Re-run `hub_monitor.py`** — 71 days stale; file-level change tracking across the hub is currently blind.
4. **Refresh PubMed data** — 3 days old, trending stale but not urgent yet.
5. Update `Diabetes_Research_Tracker.xlsx` for NCT07076199 (icodec → ACTIVE_NOT_RECRUITING), NCT07797335 (new AMBITION 7 Phase 3 trial), and the Onswik/Foundayo approvals — all still outstanding.
6. Check the stale `.git/index.lock` — a review-only session couldn't clear it; worth confirming no other process is stuck mid-write.

*This is a review-only run. No existing files were modified.*
